Indiva Stock (OTC:NDVAF), Trade Ideas

Indiva Ltd sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, the company produces and distributes award-winning cannabis products nationally, including Bhang Chocolate, Wana Sour Gummies, Slow Ride Bakery Cookies, Jewels Chewable Tablets, Ruby Cannabis Sugar, Sapphire Cannabis Salt, as well as capsules, pre-rolls and premium flower under the INDIVA and Artisan Batch brands.

Cannabis

Earnings

News

Penny Stocks

Markets

NDVAF

TSXV:NDVA

Canadian cannabis edibles producer Indiva Limited (TSXV: NDVA) (OTCQX: NDVAF) reported on Tuesday its second quarter financial results for the three months ending June 30, 2023.

Canadian Weed Edibles Producer&#39;s Q2 Financial Results Show Drop In Revenue &amp; Gross Profit, Here&#39;s Why

Small Cap

SNDL

SNDL Inc. (NASDAQ: SNDL) announced that between June 10, 2023, and June 22, 2023, SNDL disposed of 3.3 million common shares in the capital of Indiva Limited (OTCQX: NDVAF)(TSXV:NDVA) .

SNDL Lowers Its Stake In Indiva To 8.57%

Photo by Christophe Dion on Unsplash

Movers

Trading Ideas

S&amp;P Dow Jones Indices announced changes to the S&amp;P/TSX Composite Index, which will take effect on June 19, including the removal of Canopy Growth Corporation (NASDAQ: 

Cannabis Giant Canopy Growth Removed From Market Benchmark S&amp;P/TSX Composite Index

Indiva Ltd

<p>Wells Fargo  analyst Colin Langan   maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Underweight and raises the price target from $28 to $30.</p>


Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on General Motors, Raises Price Target to $30

Boeing CFO Says Q2 FCF Expected To Improve Vs Q1 But Will Still Be A "Sizeable" Burn

WIIM

LYFT

UBER

Uber and Lyft shares are trading lower. The stocks may be down on competition concerns amid robotaxi efforts from Tesla.

RUSHB

Rush Enterprises shares are trading lower after the company reported worse-than-expected Q1 revenue results.

<p>Benchmark  analyst Daniel Kurnos   reiterates Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) with a Buy and maintains $23 price target.</p>


Reiteration

DRCT

Benchmark Reiterates Buy on Direct Digital Holdings, Maintains $23 Price Target

Boeing Reports Ending Q1 With 60 Dreamliners in Inventory

<p>Keefe, Bruyette &amp; Woods  analyst Aidan Hall   downgrades Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) from Outperform to Market Perform and lowers the price target from $19 to $17.</p>


Downgrades

Keefe, Bruyette & Woods Downgrades Invesco to Market Perform, Lowers Price Target to $17

Evercore shares are trading lower after the company reported worse-than-expected Q1 sales results.

<p>Wells Fargo  analyst Elyse Greenspan   maintains Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) with a Overweight and lowers the price target from $132 to $108.</p>


Wells Fargo Maintains Overweight on Globe Life, Lowers Price Target to $108

<p>Keefe, Bruyette &amp; Woods  analyst Kelly Motta   reiterates Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) with a Market Perform and lowers the price target from $18.5 to $18.</p>


HAFC

Keefe, Bruyette & Woods Reiterates Market Perform on Hanmi Financial, Lowers Price Target to $18

<p>Novocure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.</p>
<p>METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC. In March, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.novocure.com%2Fmetis-phase-3-clinical-trial-met-primary-endpoint-demonstrating-a-statistically-significant-extension-in-time-to-intracranial-progression-for-patients-with-brain-metastases-from-non-small-cell-lung-c%2F&amp;esheet=53950834&amp;newsitemid=20240424461661&amp;lan=en-US&amp;anchor=Novocure+announced&amp;index=1&amp;md5=100ed40c07fdba32842018880ba6f0c2">Novocure announced</a> METIS met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone.</p>
<p>"We are honored to present the results of the METIS clinical trial as a late-breaking abstract this year at ASCO, the largest global oncology conference," said Asaf Danziger, Novocure's Chief Executive Officer. "Patients with brain metastases from non-small cell lung cancer need more treatment options. The METIS trial demonstrated that TTFields Therapy delayed intracranial progression while preserving neurological function, which is critical for these underserved patients. We look forward to robust discussion around the positive results of the METIS clinical trial, as well as other TTFields therapy program updates at ASCO 2024."</p>
<p>The METIS data will be presented on June 3 as a late-breaking abstract during ASCO's Central Nervous System Tumors session from 8 a.m. to 10 a.m. CDT. Lead author Minesh Mehta, MD, Chief of Radiation Oncology and Deputy Director at Miami Cancer Institute, part of Baptist Health South Florida, will give the presentation.</p>
<p>The oral presentation of the METIS clinical trial data is one of four abstracts on TTFields therapy to be included at the 2024 ASCO Annual Meeting.</p>
<p>Abstract titles from Novocure-sponsored and partner programs include:</p>
<ul>
<li><strong>Results from METIS (EF-25), an International, Multicenter Phase III Randomized Study Evaluating the Efficacy and Safety of Tumor Treating Fields (TTFields) Therapy in NSCLC Patients with Brain Metastases.</strong> Abstract 2008. 10:24 a.m. CDT on June 3.<br />&nbsp;</li>
<li><strong>Tumor Treating Fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study.</strong> Abstract 2036. 9 a.m. CDT on June 1.<br />&nbsp;</li>
<li><strong>LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. </strong>Abstract TPS8665. 1:30 p.m. CDT on June 3.<br /><br />
<ul>
<li><strong>Deep Learning Convolutional Neural Networks Reliably Monitor and Accurately Identifies Predictors of Response to Novo-TTFields.</strong> Publication Only.</li>
</ul>
</li>
</ul>


Biotech

General

NVCR

Results Of Novocure's METIS Phase 3 Clinical Trial For Patients With Brain Metastasis From Non-Small Cell Lung Cancer To Be Presented As Late-Breaking Abstract At ASCO 2024

SPDR Dow Jones Industrial Average ETF Trust

QQQM

Major indexes are higher following earnings reports across sectors. Strong earnings from TXN have lifted chip stocks while Tesla also gained following its Q1 report.

<p>Benchmark  analyst Mark Palmer   reiterates CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and maintains $8 price target.</p>


CMPO

Benchmark Reiterates Buy on CompoSecure, Maintains $8 Price Target

<p>Wells Fargo  analyst Elyse Greenspan   maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Equal-Weight and raises the price target from $84 to $85.</p>


Wells Fargo Maintains Equal-Weight on Brown & Brown, Raises Price Target to $85

Mattel shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also, DA Davidson maintained a Buy rating on the stock and raised its price target from $26 to $27.

<p>Financial giants have made a conspicuous bearish move on Chevron. Our analysis of options history for Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 25% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $157,241, and 5 were calls, valued at $135,676.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $157.5 to $172.5 for Chevron over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Chevron's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Chevron's substantial trades, within a strike price spectrum from $157.5 to $172.5 over the preceding 30 days.</p>
<h3>Chevron Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713969959_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$11.85</td>
<td>$11.55</td>
<td>$11.65</td>
<td>$172.50</td>
<td>$79.2K</td>
<td>1</td>
<td style="text-align: right;">91</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$9.85</td>
<td>$9.8</td>
<td>$9.85</td>
<td>$165.00</td>
<td>$48.2K</td>
<td>310</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$165.00</td>
<td>$29.7K</td>
<td>44</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.75</td>
<td>$17.7</td>
<td>$17.95</td>
<td>$160.00</td>
<td>$28.7K</td>
<td>395</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$5.25</td>
<td>$5.15</td>
<td>$5.2</td>
<td>$160.00</td>
<td>$28.6K</td>
<td>13.6K</td>
<td style="text-align: right;">49</td>
</tr>
</tbody>
</table>
</p>
<h3>About Chevron</h3>
<p>Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.1 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.8 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2023 stood at 11.1 billion barrels of oil equivalent, including 6.0 billion barrels of liquids and 30.4 trillion cubic feet of natural gas.</p>
<p>Following our analysis of the options activities associated with Chevron, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Chevron</h3>
<ul>
<li>Trading volume stands at 1,353,456, with CVX's price down by -0.37%, positioned at $162.25.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<h3>Expert Opinions on Chevron</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $191.6.</p>
<ul>
<li>An analyst from UBS has decided to maintain their Buy rating on Chevron, which currently sits at a price target of $197. </li>
<li>An analyst from Wells Fargo persists with their Overweight rating on Chevron, maintaining a target price of $198. </li>
<li>An analyst from Piper Sandler persists with their Overweight rating on Chevron, maintaining a target price of $204. </li>
<li>An analyst from Truist Securities has decided to maintain their Hold rating on Chevron, which currently sits at a price target of $156. </li>
<li>Reflecting concerns, an analyst from Barclays lowers its rating to Overweight with a new price target of $203.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Chevron with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Looking At Chevron's Recent Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Carvana. Our analysis of options history for Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 69% of traders were bullish, while 23% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $142,985, and 9 were calls, valued at $1,296,004.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $95.0 for Carvana during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Carvana's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carvana's whale trades within a strike price range from $65.0 to $95.0 in the last 30 days. </p>
<h3>Carvana 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713969953_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$16.5</td>
<td>$14.45</td>
<td>$15.0</td>
<td>$65.00</td>
<td>$750.0K</td>
<td>5.0K</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$17.7</td>
<td>$17.7</td>
<td>$17.7</td>
<td>$90.00</td>
<td>$146.9K</td>
<td>1.8K</td>
<td style="text-align: right;">83</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$14.35</td>
<td>$14.15</td>
<td>$14.35</td>
<td>$80.00</td>
<td>$113.3K</td>
<td>1.2K</td>
<td style="text-align: right;">229</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/26/24</td>
<td>$7.7</td>
<td>$7.15</td>
<td>$7.6</td>
<td>$70.00</td>
<td>$81.8K</td>
<td>4.4K</td>
<td style="text-align: right;">4</td>
</tr>
<tr>
<td>CVNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$7.45</td>
<td>$7.35</td>
<td>$7.45</td>
<td>$76.00</td>
<td>$61.0K</td>
<td>80</td>
<td style="text-align: right;">90</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carvana</h3>
<p>Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.</p>
<p>In light of the recent options history for Carvana, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Carvana</h3>
<ul>
<li>With a trading volume of 748,157, the price of CVNA is up by 1.36%, reaching $76.65.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
<h3>Expert Opinions on Carvana</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $75.0.</p>
<ul>
<li>An analyst from JMP Securities has revised its rating downward to Market Outperform, adjusting the price target to $80. </li>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Carvana, targeting a price of $78. </li>
<li>An analyst from Evercore ISI Group persists with their In-Line rating on Carvana, maintaining a target price of $77. </li>
<li>An analyst from Baird persists with their Neutral rating on Carvana, maintaining a target price of $65. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Carvana with a target price of $75. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Carvana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CVNA

Check Out What Whales Are Doing With CVNA

<p>Benzinga's options scanner has just identified more than 8 option transactions on Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>), with a cumulative value of $367,771. Concurrently, our algorithms picked up 2 puts, worth a total of 139,625.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $18.0 for Bilibili, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Bilibili's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bilibili's whale trades within a strike price range from $10.0 to $18.0 in the last 30 days. </p>
<h3>Bilibili Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713969948_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BILI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$5.3</td>
<td>$5.05</td>
<td>$5.15</td>
<td>$17.50</td>
<td>$103.0K</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.5</td>
<td>$1.46</td>
<td>$1.5</td>
<td>$13.00</td>
<td>$75.0K</td>
<td>3.0K</td>
<td>113</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/24/24</td>
<td>$0.68</td>
<td>$0.55</td>
<td>$0.67</td>
<td>$14.00</td>
<td>$59.6K</td>
<td>227</td>
<td>1.0K</td>
</tr>
<tr>
<td>BILI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$2.97</td>
<td>$2.91</td>
<td>$2.93</td>
<td>$14.00</td>
<td>$36.6K</td>
<td>19</td>
<td>170</td>
</tr>
<tr>
<td>BILI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$10.00</td>
<td>$34.2K</td>
<td>129</td>
<td>160</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bilibili</h3>
<p>Bilibili is a Chinese online entertainment platform that is best known for its video-sharing site that resembles YouTube. The site was founded in 2009 and started as a long-form video platform for anime, comics, and gaming, or ACG, content that appealed to Gen Z users. Since then, it has expanded its content on the platform to include a broader range of interests that have attracted Chinese users outside of the Gen Z cohort. The firm generates revenue through five main areas: advertising, games, live streaming, value-added services, and e-commerce.</p>
<h3>Present Market Standing of Bilibili</h3>
<ul>
<li>Trading volume stands at 8,236,635, with BILI's price up by 11.49%, positioned at $12.81.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bilibili with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BILI

Bilibili's Options: A Look at What the Big Money is Thinking

Guidance

Boeing CFO Says Expect To Achieve 787 Rate Increases, Including 10 Per Month By 2026

<p>Wells Fargo  analyst Elyse Greenspan   maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Overweight and lowers the price target from $99 to $94.</p>


Wells Fargo Maintains Overweight on WR Berkley, Lowers Price Target to $94

In a report released today, Andrew Semple from Echelon Wealth Partners upgraded Indiva (NDVAF – Research Report) to a Buy, with a price target of C...

Indiva's Strong Q323 Results and Anticipated Growth Drive Analyst's Buy Rating

Andrew Semple, an analyst from Echelon Wealth Partners, maintained the Buy rating on Indiva (NDVAF – Research Report). The associated price target ...

Indiva's Strong Sales and Market Share Gains Prompt Buy Rating and Raised Price Target

Indiva announces private placement under listed issuer financing exemption up to $4M

Indiva to raise up to $4M through private placement

Indiva (TSE:NDVA) has released an update. Indiva Limited, a leader in the Canadian cannabis edibles market, recently announced the filing of an ame...

Indiva Targets $4.3M Raise in Strategic Private Placement

Indiva (TSE:NDVA) has released an update. Indiva Limited, a leader in Canadian cannabis edibles, has successfully completed the first tranche of it...

Indiva Completes Initial Tranche of Private Placement

Indiva (TSE:NDVA) has released an update. Indiva, a leading Canadian cannabis edibles producer, has launched its second private placement aiming to...

Indiva Targets Up to $4M in Private Placement

Indiva (TSE:NDVA) has released an update. Indiva Limited, Canada's leading cannabis edibles producer, has amended its loan terms with SNDL Inc., en...

Indiva Adjusts SNDL Loan Terms, Explores Strategic Options

Echelon Wealth Partners analyst Andrew Semple downgraded the rating on Indiva (NDVAF – Research Report) to a Hold today, setting a price target of ...

Maintaining Hold on Indiva Amid Regulatory Challenges and Financial Uncertainty

Indiva (TSE:NDVA) has released an update. Indiva Limited, Canada's leading producer of cannabis edibles, is set to announce its full-year and fourt...